KIMS Q4 Results Review - Weak Quarter; Margins To Improve: Prabhudas Lilladher

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Krishna Institute of Medical Sciences Ltd. Q4 operating performance impacted (Ebitda de-grew at 3% YoY to Rs 1.6 billion) from weak profitability in Telangana cluster and there were certain one offs.

Our FY25E/FY26E Ebitda estimates stands reduced by 6-7%. Though FY24 had muted Ebitda growth; new clinical talent hiring and addition of sub specialties across Telangana units will see ramp up in revenues and profitability from Q2 FY25.

Further KIMS is exploring greenfield expansion in Bangalore and Maharashtra. We expect 15% Ebitda compound annual growth rate over FY24-26E with healthy return ratios of ~20%.

Maintain ‘Buy’ rating with revised target price of Rs 2,100/share (earlier Rs 2,200) based on 23 times FY26E enterprise value/Ebitda.

Delay in break-even of upcoming new units will be key risk to our call.

Click on the attachment to read the full report:

Prabhudas Lilladher KIMS Q4FY24 Results Review.pdf

Read Document

Also Read: Balkrishna Industries Q4 Results Review - Healthy Volume Growth Boosts Overall Performance: Motilal Oswal

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.